You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Integrated molecular diagnostic system for the point-of-care

    SBC: BIOHELIX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (lt SPE) column, flap valves and hydrophobic vents to gate fluid movements through micro channels, and multiple reaction chambers for experimenta ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Novel Anti-Biofilm Compounds for Treating Chronic Wounds

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Chronic wounds that fail to respond to traditional therapeutic interventions afflict millions of people each year, and direct costs associated with treating these wounds are estimated at 5 to 10 billion annually. Eradication of pathogenic bacteria that have colonized chronic wounds is complicated by the propensity of these bacteria to form ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Isolation of functional IgGs in the cytoplasm of a novel E. coli expression host

    SBC: NEW ENGLAND BIOLABS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Monoclonal antibodies (mAbs) hold great promise in human health with applications ranging from therapeutic agents that target cancer cells, to diagnostic biomarkers that can detect trace levels of a given antigen. Thispromise is best reflected in global sales of antibodies which reached nearly 31 billion in 2007 and future sales predicted to reach 56 billion ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Use of milatuzumab in modulating graft vs. host disease

    SBC: IMMUNOMEDICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Control of GVHD by milatuzumab in hu-SCID mice Dendritic cells (DCs) are the primary initiator of graft-versus-host disease (GVHD), a major and life- threatening complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). Depletion of DCs has been demonstrated to be an effective approach for control of GVHD. We recently found that milatuzumab ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Infections associated with medical devices can be serious and even fatal. Catheter colonization and production of a biofilm on the surface of a catheter shortly after implantation are normally the prelude for infections. A number of antimicrobial-treated catheters have been developed to combat these infections, however, many of them have limited clinical effica ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Anti-biofilm agents for treating pulmonary infection in Cystic Fibrosis patients

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is the most common life shortening inherited disorder amongst Caucasians, and Pseudomonas aeruginosa pulmonary infections are the leading cause of mortality in CF patients. Treatment of patients infected with P. aeruginosa is complicated by the cell-to-cell signaling systems of this organism, which regulate biofilm formation, virulence gene ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Developing small molecule therapeutics for lupus

    SBC: Biomedical Research Models, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) affects ~ 2 million Americans with devastating impact on multiple organs, especially the skin, joints, kidney, and brain. Therapeutic strategies for lupus are largely palliative orimmunosuppressive with serious toxicities. No new drugs for SLE have been approved in decades. Thus, novel therapeutic approaches to lupus - par ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as well as tumor cells. Therapeutic benefit depends on tumor cellsbeing more sensitive than normal cells, thereby allowing clinical responses to be achieved at relatively safe drug doses; however, damage t ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Towards home-fitting software for cochlear implants

    SBC: NEW FOLDER CONSULTING, LLC            Topic: NIDCD

    DESCRIPTION (provided by applicant): By the end of 2006, an estimated 23,000 adults and 15,500 children had received cochlear implants in the United States alone (www.nidcd.nih.gov). The complexity of the system as well as confounding factors such as brainplasticity and changing physiology require that these parameters be continually updated to maximize listening performance and user satisfaction. ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. High-throughput portable software for fragment-based drug design

    SBC: ACPHARIS            Topic: NIGMS

    DESCRIPTION (provided by applicant): Fragment-based drug design (FBDD) is a combinatorial approach in which individual fragments binding to regions of the target site are selected from a fragment library, and then combined to form potential lead compounds.Interest in this approach has significantly increased during the last few years, with many companies using FBDD methods based on X-ray crystallo ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government